Physician profile
Andrew Robinson
NPI 1366782567
$3,122.70
in general payments reported to CMS, 2019-2025
41 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $358 · 2021: $438 · 2022: $290 · 2023: $154 · 2024: $84.65 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.80 | 2021-2025 | Vraylar |
| Amgen INC. | $247.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $210.55 | 2019-2023 | Bexsero, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $196.58 | 2019-2021 | |
| Pfizer INC. | $187.73 | 2019-2025 | |
| Lilly USA, LLC | $175.74 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $174.48 | 2020-2025 | Aveir |
| Boston Scientific Corporation | $159.49 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Novo Nordisk INC | $151.82 | 2019-2025 | Ozempic |
| Sanofi-Aventis U.S. LLC | $107.42 | 2019-2020 | |
| Allergan, INC. | $102.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $94.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $77.77 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $72.58 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.